

IPW

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/642,255
Filing Date	August 15, 2003
First Named Inventor	DOLE et al,
Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	52339AUSM1

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

- | | | |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/
Incomplete Application
<input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication
to Technology Center (TC)
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please
Identify below):
PTO -1449 With Cited Refs.
Return Postcard |
|---|--|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Wendy L. Washtien Ph.D.
Signature	<i>Wendy L. Washtien</i>
Date	February 10, 2005


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Alishia L. Rowe-Babb		
Signature	<i>Alishia L. Rowe-Babb</i>	Date	February 10, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of DOLE et al. : Group Art Unit: 1614
Application No.: US10/642,255 : Examiner: Not Yet Known
Filed: August 15, 2003 : Docket No. 52339AUSM1
For: GENE THERAPY FOR CRITICAL LIMB ISCHEMIA WITH WILD-TYPE OR MUTANT eNOS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants which to make known to the Patent and Trademark Office the references cited on the attached form PTO-1449 (copies enclosed). The references cited on the attached form PTO-1449 include references that were first cited in a foreign search report (attached) in a counterpart foreign application not more than 3 months prior to the mailing date of this IDS. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

This Supplemental IDS is being filed before the mailing of the first Office Action on the merits as described in 37 CFR 1.97(b). Therefore, it is believed that no fee is required under 37CFR 1.97(b)(3). However, Commissioner is hereby authorized to charge any additional fees required to facilitate the filing of this application to deposit account 02-2117. This is, however, not authorization to charge the issue fee.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "Wendy L. Washten", with a long horizontal flourish extending to the right.

Wendy L. Washten, Ph.D. (Reg. No. 36,301)
Patent Agent for Applicants

Date: Feb 10, 2005

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94804-0099
Telephone No. 510-669-4483
Facsimile No. 510-262-7095
Customer No. 27586

FORM PTO-1449 (REV. 7-80)		FEB 14 2005 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 52339AUSM1		APPLICATION NO. US10/642,255	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS DOLE et al,			
				FILING DATE August 15, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	1.	KAUSER et al, Bone marrow progenitor mediated postishhemic blood flow recovery and limb salvage in a mouse model of critical limb ischemia. <i>Experimental Hematology</i> 2003					
	2.	MESSINA et al, Therapeutic angiogenesis for critical limb ischemia: invited commentary <i>Journal of Controlled Release</i> 2002. Vol. 78, pages 285-294, especially pages 285 and 287-293.					
	3.	BROUET et al, Hsp90 ensure the transition from early Ca ²⁺ -dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor exposed endothelial cells <i>The Journal of Biological Chemistry</i> , August 2001, Vol. 276, No. 35. Pages 32663-32669					
	4.	FULTON et al, Regulation of endothelium-derived nitric oxide production by the protein kinases Akt <i>Nature</i> June 1999, Vol. 399 pages 597-601					
	5.	KHURANA et al, Gene therapy for cardiovascular disease <i>Hypertension</i> 2001, Vol. 38 pages 1210-1216					
	6.						
	7.						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							